A Centralized Pathology Protocol for Global Cancer Genomics: The Mutographs Project Model v1

Read full text Summarise with VIRAT
Authors: Behnoush Abedi‐Ardekani, Arash Nikmaneshi, Masoud Sotoudeh, Valérie Gaborieau, Farid Azmoudeh-Ardalan, Hiva Saffar, Stefano Serra, Christine Carreira, Priscilla Chopard, Sophie Ferlicot, Jean‐Yves Scoazec, Christophe Lalemand
+9 more Elodie Colney, Sophie Guillot, Fatemeh Ghasemi‐Kebria, Ana Carolina de Carvalho, Aida Ferreiro-Iglesias, Sandra Perdomo, Paul Brennan, Manuel Salto‐Tellez, Gholamreza Roshandel
Cited by: 0
References: 2

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

We present the pathology workflow of the Mutographs project, a multicancer genomic initiative led by the Sanger Institute and funded by Cancer Research UK, between 2017 and 2023. Mutographs aims to elucidate differences in cancer incidence through whole genome sequencing (WGS) and mutational signature analysis of over 6,000 carcinomas of the esophagus, kidney, colorectum, pancreas, head and neck, and urinary bladder collected from 27 countries. The protocol is designed by the International Agency for Research on Cancer, where centralized pathology and paired tumor-blood DNA extraction was performed. The workflow comprises four main parts. Part 1 defines handling of frozen cancer tissues for pathology and DNA extraction, followed by multi-step pathology quality evaluation and guidance through a structured five-option approach (Part 2), including macrodissection for tumors with percentage of viable tumor cells (PVTC) 3c50% (Part 3) and laser capture microdissection for certain tumor types (Part 4). Rigorous and stepwise pathology quality control led to the overall success rate of 88% in providing high-quality DNA for WGS, while 40.9% of low-quality or non-eligible tissues were excluded. PVTC was successfully enriched in 72% of 1,804 macrodissections performed. Inter-pathologist agreement to report PVTC was substantial (ICC = 0.75, CI: 0.72–0.77). This protocol provides a reproducible fully integrated pathology–molecular pipeline in challenging conditions to ensure high-quality DNA and reliable data interpretation at an unprecedented multinational scale and could be considered as a model for high-quality tissue processing in international genomics initiatives.

Fields of Study & Subjects

Cancer Genomics and Diagnostics Cancer Diagnosis and Treatment Pancreatic and Hepatic Oncology Research

Publication details

Publication date
20 March 2026
Language
EN
Document type
Preprint